PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

EBMT Harmonizes Viral CNS Infection Care After HSCT and CAR T-Cell Therapy

★ Editor's PickEBMT Practice Harmonization and Guidelines Committeeviral encephalitismeningitismyelitisHSCTCAR T-cell therapyfoscarnetacyclovirganciclovirletermovirHHV-6 Infectious Disease / Antimicrobials

Background Information

New guidelines tackle deadly CNS infections after cancer therapies.

Infectious complications like viral encephalitis, meningitis, and myelitis post-transplant and CAR T-cell therapy have high mortality rates and are often underdiagnosed. The guideline standardizes diagnostic categories, introduces a diagnostic algorithm, and recommends immediate empirical antiviral treatment. While providing useful guidelines, these rely largely on expert opinion and observational data, highlighting the need for further research. Standardized guidelines aim to improve diagnosis and treatment of viral CNS complications post-HSCT and CAR T-cell therapy.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Piñana JL, Cesaro S, Styczynski J, Schmidt-Hieber M, Mikulska M, Neofytos D, Baccelli F, Navarro D, Onida F, Ruggeri A, Sanchez-Ortega I, Camara R, Averbuch D, Yakoub-Agha I, Ljungman P

Citation: Piñana JL, Cesaro S, Styczynski J, et al. Syndrome-oriented CNS infectious complications after hematopoietic stem-cell transplantation and CAR T-cell therapy, part 1-viral encephalitis, meningitis, and myelitis: recommendations from the Practice Harmonization & Guidelines Committee of the EBMT. EClinicalMedicine. 2026;101:104312. doi:10.1016/j.eclinm.2026.104312

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.